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A decline in mortality due to pump failure has been clearly documented after cardiac resynchronization therapy
(CRT), however the impact on sudden cardiac death and the development of malignant ventricular arrhythmias remains
questionable. Our study aims to investigate this alleged pro-arrhythmic effect of CRT using surface electrocardiogram
(ECG) markers of pro-arrhythmia.
Methods: Seventy five patients, who received CRT were included in this study. Manual measurement of corrected
QT interval (QTc), Tpeak-end (Tp-e) interval, QT dispersion (QTd) and Tpeak-end dispersion during baseline 12 lead sur-
face ECG and after applying atrial-biventricular pacing were done. Arrhythmias post CRT was recorded from ECG,
24 h holter monitoring or pacemaker programmer event recorder.
Results: QTc interval showed significant prolongation after CRT (498.9 ± 50.8 vs. 476.2 ± 41.6 msec, P = 0.0001).
Comparing patients with major arrhythmogenic events (MAE) and increased frequency of premature ventricular
contractions (PVCs) post CRT pacing to those patients without arrhythmias, there was a significant prolongation
of the QTc interval (527 ± 63.29 vs. 496.95 ± 45.2 msec, P = 0.043) and Tp-e interval (94.16 ± 9 vs. 87.41 ± 16.37 msec,
P = 0.049). While in the arrhythmogenic group, there was an insignificant decrease in QTd and Tpeak-end dispersion.
Conclusion: QTc and Tp-e intervals are a potential predictor of occurrence of MAE and PVCs. On the other hand,
Tp-e dispersion and QTd did not show a predictive potential for arrhythmia.
 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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Cardiac resynchronization therapy (CRT) hasbecome an established adjunctive treatment
to optimal pharmacologic therapy in patients with
advanced chronic heart failure. Several controlled
studies have demonstrated the efficacy of CRT in
improving hemodynamics and symptoms in the
acute setting as well as during chronic follow-up.The hemodynamic improvements begin almost
immediately after pacing is initiated as evidenced
by increases in aortic pulse pressure, left ventricu-
lar dP/dt max (rate of rise of left ventricular
pressure), and stroke volume [1,2]. Long-term re-
sults demonstrated evidence of reverse remodel-
ing, increased exercise capacity and functional
class, improved quality of life and decreased
hospitalization rates [3–7]. In addition, favorable
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apy are demonstrated by reduced sympathetic
nervous activity, [8] and increased heart rate vari-
ability [9,10].
On the other hand, the capability of CRT tech-
nology to reduce all-cause cardiac mortality is less
well established. A decline in mortality due to
pump failure has been clearly documented; [3]
however, the impact on sudden cardiac death
and the development of malignant ventricular
arrhythmias remain questionable [11,12]. Meta-
analysis of nine randomized trials of CRT showed
a significant reduction in all-cause mortality by
21% [13]. However, there was a non-significant ex-
cess in the number of sudden cardiac deaths. This
meta-analysis did not include mortality data from
two of the larger CRT studies (COMPANION [11]
and CARE-HF trials), that had the statistical
power to demonstrate mortality benefit. In the
COMPANION study there was a significant 36%
mortality reduction in CRT group (P = 0.003), as
compared to optimal medical treatment alone
group. However, sudden cardiac death accounted
for a substantially greater fraction of all deaths in
CRT versus optimal medical treatment group
(36.6% vs. 23.4%). Similarly, in CARE-HF there
was a significant decrease in all cause mortality
in the CRT group versus pharmacologic therapy
(P < 0.002). However, the percentage of sudden
deaths was higher in the CRT group versus non-
sudden cardiac deaths (35.4% vs. 31.7%).
Some studies suggest that bi-ventricular pacing
could decrease the incidence of ventricular
arrhythmia [13–16] by improving dispersion of
repolarization and neurohumoral signaling
[10,17–19]. Whereas other studies showed that
CRT does not decrease the frequency of ventricu-
lar arrhythmias [20] and might exceed to potenti-
ating a pro-arrhythmic effect [21–26] due to
reversal of myocardial depolarization through epi-
cardial stimulation as occurs in LV pacing via the
coronary sinus [21,27,28] and even promoting sud-
den – presumed arrhythmic – cardiac deaths [29].
This was supported by some case reports showing
de novo development and/or increase incidence
of ventricular arrhythmias after CRT [30–33].
In this context, our study aimed to investigate
this alleged pro-arrhythmogenic effect of cardiac
resynchronization therapy via epicardial left ven-
tricular pacing.Figure 1. Diagram demonstrating different intervals measured from
surface ECG in our study.Patients and methods
Seventy five patients were studied from June
2008 to June 2011 after informed consent fromthe patients and approval of the study by the eth-
ical committee at the Critical Care Department,
governmental Kasr Al Ainy Medical School, Cairo
University, according to the declaration of Hel-
sinki. All the patients had atrio-biventricular pace-
makers implanted as adjunct management
strategy for advanced congestive heart failure.
The following inclusion criteria were adopted: (1)
heart failure from any cause, (2) moderate-to-se-
vere HF (New York Heart Association functional
class III or IV) despite optimal medical treatment
(3) left BBB with QRS duration P120 msec, and
(4) left ventricular ejection fraction (LVEF) 635%
[34].
The ECG was recorded with a standard digital
recorder 12 simultaneous leads at a paper speed
of 25 mm/s (Nihon Kohden CardioFax GEM
ECG-9020 K Interpretive Electrocardiograph
Machine). Because of no standardized proven
experience with automatic algorithms for ECG
interval measurement, manual measurement was
performed for surface eclectrocardiographic
(ECG) markers, which are used to assess liability
of potentially life threatening arrhythmias to occur
either de novo, or for increased its frequency (i.e.,
pro-arrhythmia). These eclectrocardiographic
markers included corrected QT interval (QTc),
Tpeak–Tend (Tp-e) interval in addition to QT disper-
sion (QTd) and Tpeak-end dispersion (Fig. 1) [35–39]
Measurements were performed by two indepen-
dent and experienced personnel.
The QT interval was measured from the begin-
ning of the QRS to the end of T wave, defined as
the intersection of the tangent to the down slope
of the T wave and the isoelectric line. Since the
duration of the QT interval is heart rate depen-
dent, heart rate correction formula was applied
in our study (Bazett’s formula: QTc ¼ QTﬃﬃﬃﬃ
RR
p ). The
QT dispersion was defined as the difference be-
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the 12 leads (QTmax–QTmin) [35].
The Tp-e was measured in each precordial lead
and obtained from the difference between QT
interval and QTpeak interval; measured from the
beginning of the QRS until the peak of the T
wave. In the case of negative or biphasic T waves,
QTpeak was measured to the nadir of the T wave.
The presence of pathological U waves compli-
cates the determination of the precise QT interval
duration, when U wave overlaps with the T wave,
the end of the T wave was defined as the nadir
between the T and U waves. T peak-end disper-
sion defined as (Tp-e maximum–Tp-e minimum),
also it was calculated from the precordial leads
[36].
Sudden cardiac death (SCD) was defined as a
natural, unexpected death due to cardiac causes,
heralded by an abrupt loss of consciousness with-
in 1 h of the onset of acute symptom. For the pur-
poses of this study, major arrhythmogenic events
(MAE) were defined as a combination of SCD
and/or resuscitation from a potentially fatal ven-
tricular tachyarrhythmia [37].
Patients were followed up to 12 months. Data
were collected from the clinical follow up of the
patients and medical records including electrocar-
diograms at baseline before and after applying
CRT pacemaker. Also data from 24 h holter moni-
toring and CRT device event recorder during
interrogation by programmer were collected
(Fig. 2).Statistical analysis
The comparison of continuous variables (QTc
interval, Tpeak-end interval) assessed at baseline
and during CRT therapy was performed using
paired t-test analysis. For QT dispersion analysis
(QTmax–QTmin) and Tpeak-end dispersion analysis
(Tpeak-end max–Tpeak-end min) the nonparametric
Mann–Whitney’s or Wilcoxon matched pairs testFigure 2. CRT device event recorder tracings showing incidwere used. GraphPad software version 3.06 was
used. Statistical significance was established as P
value 60.05.Results
This study included 75 patients, with mean age
(57 ± 11.6) years, 63 (84%) were males and 12
(16%) were female. Forty patients (53.4%) had di-
lated cardiomyopathy, whereas 35 patients
(46.6%) suffered from ischemic cardiomyopathy.
Among the study group, 33 patients (44%) suf-
fered from hypertension, 29 patients (38.6%) had
diabetes, whereas 13 patients (17.4%) suffered
from both. Before device implantation, 29 patients
(38.8%) were in NYHA class III, 26 patients (34.6%)
in class III-IV, and 20 patients (26.6%) were in class
IV. As regards medical treatment for heart failure,
73 patients (97.3%) were given loop diuretics, 72
patients (96%) received spironolactone, 67 pa-
tients (89.3%) used angiotensin converting en-
zyme inhibitor (ACE-I) or angiotensin receptor
blockers (ARBS), 19 patients (25.3%) were on dig-
italis, while 46 patients (61%) were maintained
on maximum tolerated dose of B-blockers and 32
patients (42%) received amiodarone.
Sixty nine patients (92%) had CRT-P devices
while six patients (8%) had CRT-D devices im-
planted. Pacemaker trademark were 42 St. Jude
Medical and 33 Biotronik. In 46 patients the coro-
nary sinus leads were positioned in lateral branch,
16 in posterior branch, 9 in anterolateral branch
and 4 in anterior branch. AV and VV delays were
programmed empirically to 100-120 ms and 0 ms
respectively and if the patient did not respond
well, it was optimized by echocardiography. The
complications encountered were two left ventricu-
lar leads dislodgement, 5 patients with phrenic
nerve stimulation, 1 patient with pneumothorax
but all of these complications were safely solved.
During follow up after device implantation, 62
patients (82.7%) were clinical responders (definedence of ventricular arrhythmias in our study patients.
Table 1. ECG variables before and after CRT pacing in the total
study population.
Before
CRT
After CRT P
value
QRS duration (msec.) 146.9 ± 19 128 ± 16.8 0.0001
QTc (msec.) 476.2 ± 41.6 498.9 ± 50.8 0.0001
QT dispersion (msec.) 31.3 ± 14.7 31.6 ± 16.6 0.889
Tp-e interval (msec.) 89.6 ± 17.4 88.2 ± 15.7 0.377
Tp-e dispersion
(msec.)
17.5 ± 10.3 19.4 ± 7.6 0.165
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[40]). Thirty eight patients (50.7%) improved to
NYHA class I and 24 patients (32%) to class II.
On the other hand, 13 patients (17.3%) showed
no improvement in NYHA class after device
implantation (i.e., non responders). Echocardio-
graphic variables: there was a significant increase
in the ejection fraction after CRT implantation
from 30.08 ± 3.97 to 38.24 ± 4.3 (P < 0.0001). Simi-
larly, LVESV showed a significant decrease one
year post CRT from 69.4 ± 8.9 to 58.8 ± 9.5 ml
(P < 0.0001).
Effect of CRT pacing on ECG variables: it was
found that bi-ventricular pacing caused a
significant decrease in QRS duration from
146.9 ± 19 msec to 128 ± 16.8 msec (P = 0.0001). On
the other hand, the corrected QT interval showed
significant prolongation after CRT from
476.2 ± 41.6 to 498.9 ± 50.8 msec (P = 0.0001). As re-
gards QT dispersion and Tp-e dispersion, both
showed insignificant rise after bi-ventricular pac-Figure 3. Upper panel (A) showing increased frequency of PVCs post
tachycardia in the same patient.ing, while Tp-e interval showed insignificant de-
crease post CRT (Table 1).ECG variables in patients with MAE versus
patients without MAE
Major arrhythmogenic events occurred within
three months of implantation in four patients
(5.3%) in our study group. All of them were males,
three with ischemic cardiomyopathy, and one
with dilated cardiomyopathy. Three of them suf-
fered sudden cardiac death whereas the fourth
suffered from sustained ventricular tachycardia
that was managed with intravenous amiodarone
infusion (Fig. 3). These patients showed insignifi-
cant decrease in QTc, QT dispersion and Tp-e dis-
persion, whereas there was an insignificant
increase in Tp-e interval when compared to pa-
tients without MAE (Table 2).ECG variables in patients showing increased
and decreased incidence of premature
ventricular contractions (PVCS) post CRT
pacing
Eight patients (10.6%) developed increase in the
frequency of PVCs post CRT that started within
24 h post bi-ventricular pacing, three of whom
had occasional premature beats showing R on T
phenomenon (Fig. 4). These patients showed an
insignificant increase in QTc (Fig. 5), Tp-e intervals
and QT dispersion, whereas there was an insignif-CRT pacing. Lower panel (B) showing development of ventricular
FU
LL
 L
EN
G
TH
 A
RT
IC
LE
Figure 4. Post CRT pacing; 24-hour holter tracing showing PVC with R on T phenomenon.
Table 2. ECG variables in patients with MAE vs. patients without MAE. MAE = Major arrhythmogenic events, N = number.
Post CRT pacing no MAE (N = 71) MAE (N = 4) P value
QTc (msec.) 496.95 ± 45.22 487 ± 37.44 0.307
QT dispersion (msec.) 31.66 ± 17.09 25 ± 12.91 0.496
Tp-e interval (msec.) 87.41 ± 16.37 90 ± 8.16 0.062
Tp-e dispersion (msec.) 19.41 ± 6.95 18.75 ± 14.36 0.856
Figure 5. Upper panel (A) showing intrinsic rhythm with QTc = 424 msec. Lower panel (B) showing prolongation of QTc to 527 msec after
applying CRT pacing (manual measurement).
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to patients without PVCs post biventricular pacing
(Table 3).
While patients who showed a decreased inci-
dence in the frequency of PVCs post CRT showed
a significant decrease in QTc interval (426 ± 21.07
vs. 496.9 ± 45.2 msec, P = 0.043), but a non signifi-
cant increase as regards QT dispersion and Tp-e
dispersion and a non significant decline in Tp-e
interval as compared to patients without de-
creased incidence PVCs post biventricular pacing
(Table 4).ECG variables in patients showing increased
PVCS and MAE after CRT pacing
When grouping patients with MAE who devel-
oped increased frequency of PVCS post CRT into
one group and comparing them to the patients
without arrhythmias post CRT, there was a signif-
icant prolongation of the QTc interval (527 ± 63.29
vs. 496.95 ± 45.2 msec, P = 0.043) and the Tp-e inter-
val (94.16 ± 9 vs. 87.41 ± 16.37 msec, P = 0.049) in
patients with MAE and increased frequency of
PVCS. On the other hand, there was insignificant
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Table 3. Shows post CRT effect on ECG variables in patients with and without increased incidence of PVCS. Pts. = patients,
N = number, PVCS = premature ventricular contractions.
Post CRT pacing Pts. without increased
incidence of PVCS* (N = 63)
Pts. with increased
incidence of PVCS* (N = 8)
P value
QTc (msec.) 496.95 ± 45.22 547 ± 65.75 0.142
QT dispersion (msec.) 31.66 ± 17.09 32.5 ± 18.32 0.696
Tp-e interval (msec.) 87.41 ± 16.37 96.25 ± 9.16 0.065
Tp-e dispersion (msec.) 19.41 ± 6.95 18.12 ± 9.6 0.878
* Excluding patients with major arrhythmogenic events.
Table 4. Shows post CRT effect on ECG variables in patients with and without decreased incidence of PVCS. Pts. = patients,
N = number, PVCS = premature ventricular contractions.
Post CRT pacing Pts. without decreased
incidence of PVCS (N = 72)
Pts. with decreased
incidence of PVCS (N = 3)
P value
QTc (msec.) 496.95 ± 45.22 426 ± 21.07 0.043
QT dispersion (msec.) 31.66 ± 17.09 36.66 ± 5.77 0.383
Tp-e interval (msec.) 87.41 ± 16.37 80 ± 20 0.622
Tp-e dispersion (msec.) 19.41 ± 6.95 23.33 ± 5.77 0.392
Table 5. Shows post CRT effect on ECG variables in patients with and without PVCS + MAE Pts. = patients, N = number,
PVCS = premature ventricular contractions, MAE = major arrhythmogenic events.
Post CRT pacing Pts. without arrhythmias (N = 63) Pts. with increased incidence of PVCS + MAE (N = 12) P value
QTc (msec.) 496.95 ± 45.22 527 ± 63.29 0.043
QT dispersion (msec.) 31.66 ± 17.09 30 ± 16.51 0.994
Tp-e interval (msec.) 87.41 ± 16.37 94.16 ± 9 0.049
Tp-e dispersion (msec.) 19.41 ± 6.95 18.33 ± 10.73 0.964
Table 6. Shows post CRT effect on ECG variables in patients with and without clinical response to CRT.
Post CRT pacing Clinical responders (N = 62) Clinical Non responders (N = 13) P-value
QTc (msec.) 498.95 ± 48.73 498.76 ± 62.19 0.989
QT dispersion (msec.) 30.8 ± 16.22 35.38 ± 18.53 0.097
Tp-e interval (msec.) 87.17 ± 16.46 93.07 ± 10.31 0.062
Tp-e dispersion (msec.) 20.08 ± 6.98 16.15 ± 9.6 0.764
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patients with MAE and increased frequency of
PVCS (Table 5).Effect of clinical responders to CRT on paced
ECG variables
Patients showing clinical response by improving
by one or more NYHA class during follow up after
bi-ventricular pacing expressed insignificant de-
crease in QTc, and Tp-e dispersion than non
responders, while there was an insignificant rise
in QT dispersion, and Tp-e interval (Table 6).Discussion
Markers of pro-arrhythmia from surface ECG
has been studied in various clinical settings
[35–39]. We therefore used it to study the effectof CRT pacing on surface ECG as a markers of
pro-arrhythmia.
QTc interval prolongation from baseline in the
setting of heart failure, ischemic heart disease,
and usage of the antiarrhythmic medications was
found to be a strong predictor of major arrhyth-
mogenic events [36,38]. In our study, QTc showed
significant prolongation in all our study popula-
tion after biventricular pacing.
QT dispersion predicts mortality in patients
with myocardial infarction and heart failure.
[39,41] Increased QTd has also been shown to be
a marker for SCD, [42] occurrence of torsade de
pointes [27] and MAE [36]. Applying CRT pacing
in our study induced an increase in QT dispersion
that was insignificant. This is in contrast to Berger
et al [19] who demonstrated that biventricular
pacing was associated with a significant reduction
of QT dispersion.
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shown to provide the substrate for the develop-
ment of torsade de pointes especially under long
QT conditions [28,43–45]. This is more pronounced
in case of epicardial activation of the LV wall
[21,27,46,47]. Our data showed a non-significant
increased Tp-e dispersion among biventricular
paced patients.
Tp-e interval has been suggested as a surrogate
index of transmural dispersion of repolarization
[48,49]. In addition, prolonged Tp-e interval is asso-
ciated with inducibility as well as spontaneous
development of ventricular tachycardia in patients
with organic heart disease, [50–52] and is a strong
predictor of torsade de pointes.[38] Biventricular
pacing caused an insignificant decrease in Tp-e
interval in our study group. This finding was sim-
ilar to Chalil et al [36] and Medina-Ravell et al [27],
where left ventricular epicardial pacing resulted
in non-significant increase in Tp-e interval.
In our total study population, biventricular pac-
ing induced a significant increase in QTc interval.
Patients with increased frequency of PVCs post
CRT expressed no significant change in surface
ECG parameters of pro-arrhythmia in comparison
to patients without PVCs post biventricular pacing.
On the other hand, three patients (4%) showed a
decreased frequency of PVCs post CRT, they ex-
pressed a significant decrease in QTc interval
(426 ± 21.07 vs. 496.9 ± 45.2 msec, P = 0.043), and
an insignificant decline in Tp-e interval. There
were, however, insignificant increases in QTd and
Tp-e dispersion, as compared to patients without
PVCs post biventricular pacing.
In patients showing MAE there was insignificant
increase in Tp-e interval (P = 0.062), while QTc,
QTd, and Tp-e dispersion shows insignificant de-
cline as compared to patients without MAE. Pa-
tients with MAE and those who developed
increased frequency of PVCS post CRT were
placed in one group and compared to the group
of patients without arrhythmias. In the latter
group, there was a significant prolongation both
of the QTc interval (527 ± 63.29 vs.
496.95 ± 45.2 msec, P = 0.043) and Tp-e interval
(94.16 ± 9 vs. 87.41 ± 16.37 msec, P = 0.049), while
there was an insignificant decrease in QTd and
Tp-e dispersion in the former group.
One finding of our study is that pro-arrhythmic
ECG markers started developing almost immedi-
ately after applying biventricular pacing and that
MAE occurred in the early post implantation per-
iod (within three months in our study) which
agrees with the findings of Turitto et al. [32] Luo
Nian-sang et al. [52] and Kurita et al. [53].Conclusion
CRT delays death from progressive HF, but not
from all causes, namely presumed sudden
arrhythmic deaths. In that context, we conducted
our study aiming to develop strategies to predict
the alleged pro-arrhythmic effect induced by
CRT using LV epicardial biventricular pacing.
We concluded that QTc and Tp-e intervals seem
to be a potential predictor of occurrence of MAE
and less serious arrhythmogenic events (PVCs).
On the other hand, Tp-e dispersion and QTD did
not show a similar potential for arrhythmia
prediction.Study limitations
Study was conducted on a relatively small num-
ber of cases. A relatively larger number is needed
to confirm these results. Manual measurement of
ECG variables can be inaccurate, but no single
automated measurement method has been vali-
dated yet. However, in our study there has been
a fairly acceptable inter and intra-observer repro-
ducibility of manual measurements of the various
ECG intervals used.References
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